COSENTYX 75 MG / 0.5 ML
SECUKINUMAB : 75 MG / 0.5 ML · DIN 02525569 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is COSENTYX?
COSENTYX 75 MG / 0.5 ML contains SECUKINUMAB : 75 MG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02525569, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 02-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is COSENTYX used for?
COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis when the response to previous disease - modifying anti - rheumatic drug (DMARD) therapy has been inadequate. COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy. COSENTYX is indicated for the treatment of active non - radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C - reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately, or are intolerant to nonsteroidal anti - inflammatory drugs (NSAIDs). COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (acne inversa) who have responded inadequately to conventional systemic hidradenitis suppurativa therapy. COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 year and older who are candidates for systemic therapy or phototherapy. COSENTYX is indicated for the treatment of active enthesitis - related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. COSENTYX is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02525569 |
|---|---|
| Brand name | COSENTYX |
| Generic / active ingredient | SECUKINUMAB : 75 MG / 0.5 ML |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 75 MG / 0.5 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | L04AC10 SECUKINUMAB |
| AHFS class | 90:24.20.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Jun-2022 |
| Original market date | 2022-06-02 00:00:00 |
How is it stored and handled?
null
How is it supplied?
75 mg/0.5 mL in a carton containing one (1) pre - filled glass syringe; 150 mg/mL in a carton containing one (1) pre - filled glass syringe; 150 mg/mL in a carton containing two (2) pre - filled glass syringes; 150 mg/mL in a carton containing one (1) pre - filled SensoReady pen; 150 mg/mL in a carton containing two (2) pre - filled SensoReady pen; 300 mg/2 mL in a carton containing one (1) pre - filled glass syringe; 300 mg/2 mL in a carton containing one (1) pre - filled UnoReady pen; 150mg/mL single use vial* (lyophilized powder)
What can be used instead?
Other Canadian products sharing ATC code L04AC10 SECUKINUMAB. 5 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| COSENTYX | 150 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02438070 |
| COSENTYX | 150 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02547724 |
| COSENTYX | 300 MG / 2 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02529653 |
| COSENTYX | 300 MG / 2 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02529661 |
| COSENTYX | 150 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | APPROVED | DIN 02438062 |
Who else supplies SECUKINUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SECUKINUMAB appears in 69 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.